NorthWest Biotherapeutics Inc (NWBO)

[Roman516]

Corrections regarding NWBO.

NWBO does not employ any researchers to further develop DCVAX,
Not true, NWBO has partnerships with UCLA, Cambridge University, and multiple other research centers.
NWBO staff diminished from 20 to 16 people.
Not true, https://stockanalysis.com/stocks/nwbo/statistics/ NWBO employees (22) as of Feb 2nd, 2024.
NWBO does not have a certified CFO needed to manage the hundreds of millions that large pharma is supposed to invest for the joint trials
Not true, LP is more than capable to lead NWBO.
NWBO does NOT have any sales supporting DCVAXL after DCVAXL is approved in the UK this year.
Not true, sales support is the last stage in the product development process.
NWBO has stopped developing Flaskworks.
Not true, the Flaskworks "EDEN" unit is the last of three phases of the Flaskworks product and has been extensively tested and no need for further development.
DCVAXL for pediatrics has not started
No new SAP/SPA for new trials have been submitted to the FDA